NCT07509034 2026-04-16
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
Clinical Trials
21 trialsNCT07297667 2026-04-13
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Canadian Cancer Trials Group
Phase 1 Not yet recruiting
NCT07444710 2026-04-13
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07444632 2026-03-27
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT04579523 2026-03-13
²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1 Not yet recruiting
NCT07304154 2026-03-10
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Gilead Sciences
Phase 1 Not yet recruiting
NCT07300475 2026-02-13
Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients
Washington University School of Medicine
Phase 1 Not yet recruiting
NCT07390539 2026-02-05
B7-H3.CD28Z.CART in CNS Neoplasms
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07367685 2026-01-26
Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
The Second Affiliated Hospital of Fujian Medical University
Phase 1 Not yet recruiting
NCT07358260 2026-01-22
B7-H3.CD28Z.CART in Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07278856 2025-12-12
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT07225439 2025-11-06
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT07199413 2025-09-30
Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT06698744 2025-09-23
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT07105176 2025-08-19
HS-IT101 Injection for Advanced NSCLC
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 1 Not yet recruiting
NCT07120607 2025-08-13
Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia
Anhui Provincial Hospital
Phase 1 Not yet recruiting
NCT07024147 2025-06-17
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
Phase 1 Not yet recruiting
NCT06996119 2025-05-30
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT06277804 2024-02-26
A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor
Letolab
Phase 1 Not yet recruiting
NCT05582590 2024-01-16
Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers
NexImmune Inc.
Phase 1 Not yet recruiting